Sonoma Pharmaceuticals, Inc. (SNOA) stock
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.05 (-5.21%)
Close on Nov 17, 2026Market cap $3.99MP/E –Yield –
Sonoma Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Sonoma Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 38.9%. For fiscal 2026 it was 38.0%, against 38.2% the year before. The highest annual figure on record is 69.5% in fiscal 2013.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 38.0% | −0.3 |
| FY2025 | Mar 31, 2025 | 38.2% | +1.0 |
| FY2024 | Mar 31, 2024 | 37.3% | +3.5 |
| FY2023 | Mar 31, 2023 | 33.7% | +2.1 |
| FY2022 | Mar 31, 2022 | 31.6% | −3.6 |
| FY2021 | Mar 31, 2021 | 35.2% | −10.1 |
| FY2020 | Mar 31, 2020 | 45.3% | −1.5 |
| FY2019 | Mar 31, 2019 | 46.8% | +2.9 |
| FY2018 | Mar 31, 2018 | 43.9% | −0.3 |
| FY2017 | Mar 31, 2017 | 44.2% | +15.9 |
| FY2016 | Mar 31, 2016 | 28.3% | −24.3 |
| FY2015 | Mar 31, 2015 | 52.6% | −8.8 |
| FY2014 | Mar 31, 2014 | 61.4% | −8.1 |
| FY2013 | Mar 31, 2013 | 69.5% | +1.1 |
| FY2012 | Mar 31, 2012 | 68.4% | +5.4 |
| FY2011 | Mar 31, 2011 | 63.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | 40.2% | +3.8 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | 39.2% | −1.5 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | 37.9% | +2.3 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | 37.8% | −0.2 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | 36.5% | −2.1 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 40.7% | +9.0 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | 35.6% | −10.9 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | 38.0% | +1.8 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | 38.5% | +3.4 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | 31.7% | +3.1 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | 46.5% | +18.3 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | 36.3% | −9.9 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | 35.1% | −6.2 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | 28.7% | +24.5 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | 28.2% | −13.2 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | 46.1% | +13.0 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | 41.3% | +1.9 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | 4.2% | +13.2 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | 41.5% | +1.0 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | 33.1% | −10.2 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | 39.4% | +0.3 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -9.0% | −47.3 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | 40.4% | −5.1 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 43.4% | −2.6 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | 39.1% | −11.9 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | 38.3% | −4.5 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | 45.5% | −8.4 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | 46.0% | −3.1 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | 51.0% | +11.4 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | 42.8% | +6.3 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | 53.9% | +5.0 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | 49.1% | +6.4 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | 39.6% | −6.3 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | 36.4% | −11.9 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | 48.9% | −1.9 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | 42.7% | +5.7 |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | 45.9% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | 48.3% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | 50.8% | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | 37.0% | – |
See a number that looks wrong?